Title

Product

Pathophysiology | Mechanism of Action |

Disease Overview | Product Overview | Preclinical & Phase I Clinical Trials | Phase II Clinical Trials | Phase III Clinical Trials | Congress Data | Additional Clinical Trails

PRODUCT XXX

Onboarding Tool

Table of Contents

XXXXXX: Mechanism of Action

- Antibodies specifically bind to their target
- Prevents repeated YYYYYYYY trigeminal nociceptive transmission and decreases headache frequency over time
- Clinical efficacy appears to be mediated via ZZZZZZ action



Pathophysiology

Product

- XXXXXX is a complex neurological disorder, characterized by localized, intense, throbbing or pulsing sensations in the head (recurrent unilateral headache)
- Symptoms include nausea, vomiting, photophobia and phonophobia
- XXXXX pain occurs when peripheral nociceptors (e.g. meningeal) are stimulated and pathways of the peripheral or central nervous system (CNS) are activated inappropriately
- XXXXX pain is caused by activation and sensitization of the TGVS and release of various neuropeptides at the meninges (CGRP, calcitonin, substance P) leading to XXXXX
- A neuropeptide has been indicated as playing a key role in migraine pathology and pain perception leading to migraine attack including:
  1. Vasodilation
  2. Neurogenic inflammation
  3. Mast cell degranulation
  4. Sensory signaling activation
  5. Peripheral sensitization